Skip to main content

Fabry Disease — Deal Benchmarks & Valuation

Median Upfront
$274M
Range: $127M - $421M
Total Deal Value
$2.2B
Range: $1.2B - $3.1B
Royalty Rate
9.8% - 18.4%
Tiered up to 22.4%
Dev Milestones
$565M
Range: $318M - $812M
Model Your Deal

Market Analysis

Fabry Disease is one of the most actively transacted indications in metabolic licensing. Phase 1 deals for fabry disease carry a median total deal value of $2.2B, with upfront payments ranging from $127M to $421M. The recommended deal structure allocates approximately 13% to upfront payments and 87% to milestones.

Milestone structures for fabry disease deals allocate $565M to development milestones, $471M to regulatory milestones, and $848M to commercial milestones. Royalty rates range from 9.8% to 18.4% at the base tier, with tiered escalation reaching 13.8%-22.4% on peak sales.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for fabry disease licensing?
Phase 1 fabry disease licensing deals average $274M in upfront payments with $2.2B total deal value. The 13/87 upfront/milestone split reflects the risk profile at this clinical stage.
What royalty rates are standard for fabry disease deals?
Base royalty rates for fabry disease transactions range from 9.8% to 18.4%, with tiered escalations reaching 13.8%-22.4% on peak sales. Rates are influenced by mechanism differentiation, competitive positioning, and territorial scope.
How are fabry disease deal milestones structured?
Fabry Disease deals allocate approximately 87% of total deal value to milestones. Development milestones ($565M) make up the largest share, followed by commercial milestones ($848M) and regulatory milestones ($471M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Obesity Deals

View

Type 2 Diabetes Deals

View

NASH / MASH Deals

View

Metabolic Deal Overview

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included